Evolution of clinical trials in multiple sclerosis

Yinan Zhang, Amber Salter, Erik Wallström, Gary Cutter, Olaf Stuve

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern MS trials present earlier and with milder disease compared with historic MS populations. While placebo-controlled trials for some questions may still be relevant, DMT trials in relapsing–remitting MS (RRMS) are no longer ethical. The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects. Efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity. In trials for progressive forms of MS (PMS), the lack of sensitive outcome measures that can be used in shorter-term trials have delayed the development of effective treatments. Recent shifting of the focus to advancing trials in PMS has identified paraclinical outcome measurements with improved potential, and the testing of agents for neuroprotection and remyelination is in progress.

Original languageEnglish (US)
JournalTherapeutic Advances in Neurological Disorders
Volume12
DOIs
StatePublished - Feb 1 2019
Externally publishedYes

Fingerprint

Multiple Sclerosis
Clinical Trials
Therapeutics
Placebos
Sample Size
Magnetic Resonance Imaging
Outcome Assessment (Health Care)
Safety
Costs and Cost Analysis
Population

Keywords

  • clinical trials
  • diagnostic criteria
  • multiple sclerosis
  • outcome measure
  • progressive multiple sclerosis
  • trial design

ASJC Scopus subject areas

  • Pharmacology
  • Neurology
  • Clinical Neurology

Cite this

Evolution of clinical trials in multiple sclerosis. / Zhang, Yinan; Salter, Amber; Wallström, Erik; Cutter, Gary; Stuve, Olaf.

In: Therapeutic Advances in Neurological Disorders, Vol. 12, 01.02.2019.

Research output: Contribution to journalReview article

Zhang, Yinan ; Salter, Amber ; Wallström, Erik ; Cutter, Gary ; Stuve, Olaf. / Evolution of clinical trials in multiple sclerosis. In: Therapeutic Advances in Neurological Disorders. 2019 ; Vol. 12.
@article{8de39c183e9c42358883cc3d366d3f99,
title = "Evolution of clinical trials in multiple sclerosis",
abstract = "Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern MS trials present earlier and with milder disease compared with historic MS populations. While placebo-controlled trials for some questions may still be relevant, DMT trials in relapsing–remitting MS (RRMS) are no longer ethical. The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects. Efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity. In trials for progressive forms of MS (PMS), the lack of sensitive outcome measures that can be used in shorter-term trials have delayed the development of effective treatments. Recent shifting of the focus to advancing trials in PMS has identified paraclinical outcome measurements with improved potential, and the testing of agents for neuroprotection and remyelination is in progress.",
keywords = "clinical trials, diagnostic criteria, multiple sclerosis, outcome measure, progressive multiple sclerosis, trial design",
author = "Yinan Zhang and Amber Salter and Erik Wallstr{\"o}m and Gary Cutter and Olaf Stuve",
year = "2019",
month = "2",
day = "1",
doi = "10.1177/1756286419826547",
language = "English (US)",
volume = "12",
journal = "Therapeutic Advances in Neurological Disorders",
issn = "1756-2856",
publisher = "SAGE Publications Ltd",

}

TY - JOUR

T1 - Evolution of clinical trials in multiple sclerosis

AU - Zhang, Yinan

AU - Salter, Amber

AU - Wallström, Erik

AU - Cutter, Gary

AU - Stuve, Olaf

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern MS trials present earlier and with milder disease compared with historic MS populations. While placebo-controlled trials for some questions may still be relevant, DMT trials in relapsing–remitting MS (RRMS) are no longer ethical. The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects. Efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity. In trials for progressive forms of MS (PMS), the lack of sensitive outcome measures that can be used in shorter-term trials have delayed the development of effective treatments. Recent shifting of the focus to advancing trials in PMS has identified paraclinical outcome measurements with improved potential, and the testing of agents for neuroprotection and remyelination is in progress.

AB - Clinical trials have advanced the treatment of multiple sclerosis (MS) by demonstrating the safety and efficacy of disease-modifying therapies (DMTs). This review discusses major changes to MS clinical trials in the era of DMTs. As treatment options for MS continue to increase, patients in modern MS trials present earlier and with milder disease compared with historic MS populations. While placebo-controlled trials for some questions may still be relevant, DMT trials in relapsing–remitting MS (RRMS) are no longer ethical. The replacement of the placebo arm by an active comparator arm in trials have raised the cost of trials by requiring larger sample sizes to detect on-study changes in treatment effects. Efforts to improve trial efficiency in RRMS have focused on exploring adaptive designs and relying on sensitive magnetic resonance imaging measures of disease activity. In trials for progressive forms of MS (PMS), the lack of sensitive outcome measures that can be used in shorter-term trials have delayed the development of effective treatments. Recent shifting of the focus to advancing trials in PMS has identified paraclinical outcome measurements with improved potential, and the testing of agents for neuroprotection and remyelination is in progress.

KW - clinical trials

KW - diagnostic criteria

KW - multiple sclerosis

KW - outcome measure

KW - progressive multiple sclerosis

KW - trial design

UR - http://www.scopus.com/inward/record.url?scp=85062016593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062016593&partnerID=8YFLogxK

U2 - 10.1177/1756286419826547

DO - 10.1177/1756286419826547

M3 - Review article

C2 - 30833985

AN - SCOPUS:85062016593

VL - 12

JO - Therapeutic Advances in Neurological Disorders

JF - Therapeutic Advances in Neurological Disorders

SN - 1756-2856

ER -